Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 4/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | LDHA | P00338 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2058886 | 1.00 | ACACB (0.53) | ACACBPTPN1ALDH1A1PTGS2LTA4H | |
| Hydrochloric Acid SCHEMBL1310837 | 0.98 | ACACB (0.52) | ACACBPTPN1ALDH1A1PTGS2LTA4H | |
| Hydrochloric Acid SCHEMBL1310835 | 0.98 | ACACB (0.52) | ACACBPTPN1ALDH1A1PTGS2LTA4H | |
| SCHEMBL2311154 | 0.88 | ACACB (0.50) | ACACBPTPN1LTA4HLDHACTSL | |
| SCHEMBL2311151 | 0.88 | ACACB (0.50) | ACACBPTPN1LTA4HLDHACTSL | |
| SCHEMBL3729750 | 0.88 | ACACB (0.50) | ACACBPTPN1LTA4HLDHACTSL | |
| SCHEMBL16080173 | 0.88 | ACACB (0.50) | ACACBPTPN1LTA4HLDHACTSL | |
| Hydrochloric Acid SCHEMBL3745279 | 0.87 | ACACB (0.49) | ACACBPTPN1ALDH1A1LTA4HLDHA | |
| SCHEMBL8751946 | 0.87 | ACACB (0.49) | ACACBPTPN1LTA4HLDHACTSL | |
| Hydrochloric Acid SCHEMBL29398263 | 0.87 | ACACB (0.49) | ACACBPTPN1ALDH1A1LTA4HLDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110082087-A1 | COMPOUNDS FOR TREATING PAIN | Edificio ICAT (PT) | 2011-04-07 | — | — | US | disclosed |
| US-20110082087-A1 | COMPOUNDS FOR TREATING PAIN | Edificio ICAT (PT) | 2011-04-07 | — | — | US | disclosed |
| WO-2009123487-A1 | COMPOUNDS FOR TREATING PAIN | BIOALVO - SERVIÇOS, INVESTIGAÇÃO E DESENVOLVIMENTO EM BIOTECNOLOGIA S.A. (PT) | 2009-10-08 | — | — | WO | disclosed |
| US-7511063-B2 | High affinity quinoline-based kinase ligands | SCHERING CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-20080045568-A1 | Novel high affinity quinoline-based kinase ligands | SCHERING CORPORATION | 2008-02-21 | — | — | US | disclosed |
| US-6423689-B1 | Peptidyl calcium channel blockers | WARNER-LAMBERT COMPANY | 2002-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045568-A1 | Novel high affinity quinoline-based kinase ligands | CDKL2, CDK2, CDKL1 | ACACB 2110/4885PTPN1 2030/4885ALDH1A1 4640/4885 |
| US-20110082087-A1 | COMPOUNDS FOR TREATING PAIN | PTGS2, CNR2, PTGS1 | ACACB 1199/4885PTPN1 3524/4885ALDH1A1 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.